Results 201 to 210 of about 93,819 (293)

Multi-Patient Analysis of Steroid-Induced Hyperglycemia in Diabetic Patients Using Continuous Glucose Monitoring. [PDF]

open access: yesJ Pain Res
Birthi P   +7 more
europepmc   +1 more source

Sustained Remission of Pediatric Bowel‐Associated Dermatosis‐Arthritis Syndrome With Risankizumab

open access: yesPediatric Dermatology, EarlyView.
ABSTRACT Bowel‐associated dermatosis‐arthritis syndrome (BADAS) is a rare neutrophilic dermatosis characterized by recurrent fever, arthralgias, and skin eruptions, most commonly occurring in patients with inflammatory bowel disease. We report the case of a 17‐year‐old female with Crohn's disease who developed BADAS and achieved complete and durable ...
Kylie E. Peake   +4 more
wiley   +1 more source

Analgesic effects of platelet‐rich fibrin (PRF): A systematic review

open access: yesPeriodontology 2000, EarlyView.
Abstract Background Platelet‐rich fibrin (PRF), a second‐generation autologous platelet concentrate, has gained significant interest for its anti‐inflammatory and regenerative characteristics. While its role in tissue healing is well‐recognized, the analgesic potential of PRF remains under‐investigated.
Nathan E. Estrin   +6 more
wiley   +1 more source

ARDS and corticosteroids: beyond COVID-19. [PDF]

open access: yesPneumonia (Nathan)
Esperatti M, Olmos M, Fuentes N.
europepmc   +1 more source

Comparative 3‐Year Allograft Outcomes for Recipients of Kidneys From SARS‐CoV‐2 NAT‐Positive Donors

open access: yesTransplant Infectious Disease, EarlyView.
In this retrospective single‐center study of 220 kidney transplants from SARS‐CoV‐2 NAT+, NAT+ with COVID as cause of death (CoV‐COD) and NATneg donors, we found no significant difference in rejection or kidney pathologies at 1 year, and death, graft loss, or eGFR at 3 years by CoV‐donor status.
Christine E. Koval   +5 more
wiley   +1 more source

Bridging the Gap Between General and Transplant Infectious Disease Practice

open access: yesTransplant Infectious Disease, EarlyView.
ABSTRACT The population of iatrogenic immunocompromised individuals is steadily rising as we continue to improve in our ability to manage diseases, including cancer, autoimmune disease, and end‐organ dysfunction, with increasing access to novel agents and transplantation.
Jeremey Walker   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy